HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ROCHE's HIVID APPROVED FOR MONOTHERAPY IN HIV-INFECTED PATIENTS; NEW INDICATIONS FOR COMBINATION THERAPY WITH RETROVIR COME UNDER ACCELERATED APPROVAL

Executive Summary

Roche's Hivid is approved for second-line monotherapy in HIV- infected patients who experience disease progression with zidovudine treatment or who are intolerant to zidovudine. The new indication was approved Aug. 5.
Advertisement

Related Content

Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
AstraZeneca To Revisit Iressa Dosing Following Failed Survival Study
AstraZeneca To Revisit Iressa Dosing Following Failed Survival Study
Advertisement
UsernamePublicRestriction

Register

PS024904

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel